Misoprostol Inhibits the Cutaneous Late-Phase Allergic Response to Antigens. Results of a Double-Blind Placebo-Controlled Randomized Study and an Investigation Into the Mechanism of Action

Alam, R.; A, DeJarnatt; Stafford, Scott L.; Pa, Forsythe; Kumar, Deependra; Ja, Grant

doi:10.1097/00045391-199510000-00003

Cited by 3 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, in human allergic subjects MSP has been shown not to reduce the severity of immediate phase reactions after allergen injections 12,13 . The importance of such reaction in the pathogenesis of canine AD is questionable 32 and type 1 receptor antagonist antihistamines are known to be poorly effective in this disease 3 .…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, it appears to be effective in reducing clinical signs of aspirin‐induced asthma in human patients 11 . In cutaneous allergic inflammation, MSP inhibits the development of late‐phase reactions following intradermal allergen injections, whereas this drug has no effect on the prevention of immediate reactions 12,13 . This inhibition of cutaneous late‐phase reactions is associated with a reduction in eosinophil chemotaxis and cytokine‐stimulated eosinophil survival 13 .…”

Section: Introductionmentioning

confidence: 99%

“…In cutaneous allergic inflammation, MSP inhibits the development of late‐phase reactions following intradermal allergen injections, whereas this drug has no effect on the prevention of immediate reactions 12,13 . This inhibition of cutaneous late‐phase reactions is associated with a reduction in eosinophil chemotaxis and cytokine‐stimulated eosinophil survival 13 . Histamine release from basophils and mast cells following allergen‐specific and nonallergenic stimulation also is inhibited by MSP, even at very low concentrations 14,15 .…”

Section: Introductionmentioning

confidence: 99%

“…12,13 This inhibition of cutaneous late-phase reactions is associated with a reduction in eosinophil chemotaxis and cytokine-stimulated eosinophil survival. 13 Histamine release from basophils and mast cells following allergen-specific and nonallergenic stimulation also is inhibited by MSP, even at very low concentrations. 14,15 Misoprostol also reduces the secretion, by endotoxinstimulated monocytes, of the pro-inflammatory cytokines interleukin-1 beta and tumour necrosis factor-alpha (TNF α ).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A randomized controlled trial of misoprostol monotherapy for canine atopic dermatitis: effects on dermal cellularity and cutaneous tumour necrosis factor‐alpha

Olivry

Dunston

Rivierre

et al. 2003

Veterinary Dermatology

View full text Add to dashboard Cite

In this blinded randomized placebo-controlled trial, 20 dogs with atopic dermatitis (AD) were given placebo (8 dogs) or misoprostol (12 dogs) at 5 micro g kg-1, orally, three times daily for 3 weeks. Administration of the active drug, but not of placebo, led to a significant decrease in lesional and pruritus scores. The median reduction from baseline of both scores was approximately 30%. Misoprostol therapy did not lead to decreases of dermal cell counts or skin tumour necrosis factor (TNF)alpha mRNA copy numbers that were significantly different from those of placebo. Skin TNFalpha protein production, assessed using indirect immunofluorescence, decreased or remained unchanged in dogs receiving misoprostol. In contrast, post treatment TNFalpha fluorescence scores were higher in all but two dogs given placebo. The changes from baseline of TNFalpha fluorescence scores did not correlate significantly with those of lesional or pruritus indices. These observations confirm the modest efficacy of misoprostol for treatment of canine AD and suggest that its mild anti-allergic effects are not associated with either inhibition of inflammatory cell emigration or TNFalpha production.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A randomized controlled trial of misoprostol monotherapy for canine atopic dermatitis: effects on dermal cellularity and cutaneous tumour necrosis factor‐alpha

Olivry

Dunston

Rivierre

et al. 2003

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

“…Misoprostol is as ynthetic analogue of prostaglandin E1 that is knowntoattenuate the inflammatoryprocess andpromote collagenf ormation. This is accomplished through inhibitionofinterleukin-1beta, tumourn ecrosis factor-alpha andb eta, and thromboxanet ogetherw ith the promotion of cAMPgeneration andtype Iand type II collagenp roduction (2)(3)(4)(5)(6)(7)(8). Oral administration of misoprostol hasbeen showntobe efficacious in promoting the healing of gastro-intestinalulcersand promotion of type I andtype II collagenformation from chrondrocyteso fo steoarthritic cartilage in humans (9)(10)(11)(12)(13)(14).M ore recents tudiesh ave shownt hatt opicallya pplied misoprostol maya ppreciably promote healing of challenging wounds encounteredfollowing radiation therapy,prevent the formation of mucositis in irradiatedpharyngeal andoralmucosa of humans,p romote regeneration of periodontalt issues, and stimulate bone growth (14)(15)(16)(17)(18).…”

Section: Introductionmentioning

confidence: 99%

An investigation of misoprostol in the promotion of wound healing

Vandervoort¹,

Nieves²,

Fales-Williams³

et al. 2006

Vet Comp Orthop Traumatol

View full text Add to dashboard Cite

Misoprostol is a synthetic analogue of prostaglandin E1 that is known to attenuate the inflammatory process and promote collagen formation by inhibiting IL-1 and TNF. The objective of this study was to determine if the application of misoprostol wound powder to open wounds in dogs would modulate inflammation and decrease wound healing time. This prospective randomized study included 20 dogs with 281 surgically created 8 mm open wounds over the dorsum. The wounds were assigned to one of three treatments: control (no treatment), treatment (misoprostol powder with 'avicel'), or vehicle ('avicel' alone). Open wounds were digitally photographed on days zero, one, three, seven, 10, and 15 to measure wound size. All wounds were harvested at day 15 and evaluated histologically for evidence of edema, inflammation, necrosis, and collagen characteristics. Amount of epithelialization of open wounds was not significantly different among the groups at days three, seven, 10, and 15. The vehicle treated wounds were found to have a significantly higher degree of necrosis in comparison to control and treatment wounds. The control wounds had significantly lower scores for deep inflammation. All of the other parameters evaluated including location of wound, oedema, and characteristics of collagen fibres in the wound showed no significance among groups. However, the total wound score for the misoprostol was statistically higher than that for the control wounds. Therefore the value of using misoprostol wound powder with 'avicel' as the vehicle to enhance wound healing cannot be substantiated by the results of this study.

show abstract